Ozempic for women: benefits, side effects, and what to know

Ozempic has become closely associated with weight loss, but that is not what the medication was originally approved to treat.

Ozempic contains semaglutide, a GLP-1 medication used to treat type 2 diabetes and reduce certain related health risks. Semaglutide is also the active ingredient in Wegovy, which is approved for chronic weight management in certain people. The two medications contain the same active ingredient, but they have different FDA-approved uses and dosing.That distinction matters. Much of the research people hear about semaglutide and weight loss comes from studies using the higher doses associated with Wegovy - not necessarily Ozempic as it is prescribed for diabetes.

For women, there are additional questions to consider. Research suggests women may lose somewhat more weight on GLP-1 medications than men. Semaglutide may also intersect with health issues that disproportionately or uniquely affect women, including PMOS (formerly PCOS), fertility, pregnancy planning, menopause, and changes in muscle and bone health with age.

Here’s what we know, what we’re still learning, and what women should discuss with a clinician before starting treatment.

How Ozempic works for female bodies

Ozempic belongs to a class of medications called GLP-1 receptor agonists.

GLP-1 is a hormone your body naturally releases after you eat. Among other things, it helps your body release insulin when blood sugar is elevated, reduces the amount of glucose released by the liver, slows the movement of food through the stomach, and sends signals involved in appetite and fullness.

Semaglutide mimics those effects but remains active much longer than the GLP-1 your body produces naturally. That allows it to be given as a once-weekly injection. For many people, two effects are especially noticeable: feeling full sooner and experiencing less hunger or fewer cravings. Some people describe the latter as a reduction in “food noise” - the persistent thoughts about food, eating, and cravings that can make weight management difficult.

Slower stomach emptying also helps explain many of semaglutide’s most common side effects, including nausea, bloating, constipation, diarrhea, reflux, and vomiting.

Does Ozempic work differently for women?

There is evidence that women may lose more weight on GLP-1 medications than men, although researchers are still working to understand why.

A systematic review of 14 trials across five GLP-1 medications found that females lost more weight than males, and a published analysis of major semaglutide trials showed the same general pattern.

This does not necessarily mean semaglutide works through a uniquely female biological pathway. The prescribing information does not identify sex itself as having a clinically meaningful effect on how semaglutide is processed by the body. Body size and drug exposure may help explain some of the difference: at the same dose, people with lower body weight may have greater exposure to semaglutide. Hormonal, metabolic, and behavioral factors could also contribute, and more research is needed.

The practical takeaway is simpler: your response to a GLP-1 is individual. The goal should not be to reach the highest dose as quickly as possible, but to find a dose that provides benefit while keeping side effects manageable.

Ozempic Benefits for Females

It protects the heart, kidneys, and liver

Semaglutide's cardiovascular and kidney benefits are the best-evidenced things about it, and they are the reasons it is approved at all. In the trials behind those approvals, it reduced the combined risk of cardiovascular death, heart attack, stroke, and slowed kidney function decline, in women and men alike. For women after menopause, whose cardiac risk climbs sharply, that matters more than the scale does.

Liver disease is the newer finding. Metabolic dysfunction-associated steatohepatitis is common, frequently silent, and often missed in women who are not visibly heavy. A phase 3 trial found resolution of steatohepatitis without worsening fibrosis in 62.9% of participants versus 34.3% on placebo at 72 weeks, using semaglutide at 2.4 mg, the Wegovy dose.

It can restore ovulation in PMOS

Insulin resistance sits underneath much of PMOS (formerly PCOS): irregular or absent cycles, elevated androgens, acne, unwanted hair growth, and stubborn weight. GLP-1 medications improve insulin sensitivity directly, which is why they have drawn so much interest here despite not being approved for the condition.

The evidence is promising but inconclusive. A meta-analysis of 11 randomized trials found GLP-1 medications improved menstrual regularity and natural pregnancy rates, while a more recent review concluded the evidence on menstrual regularity was still insufficient to call. What is not disputed is that improving insulin sensitivity can restore ovulation in women who had stopped ovulating. PMOS weight gain is among the clearest cases where the metabolic benefit may outweigh the side effect burden.

Reduce perimenopause and menopause belly fat

The menopause transition moves fat from hips and thighs to the abdomen, and that visceral fat around the liver and pancreas is the kind most tied to heart and metabolic risk. This is where semaglutide has a specific advantage, it preferentially reduces visceral fat, the exact depot menopause deposits.

Hormone therapy appears to amplify the effect. A Mayo Clinic study found postmenopausal women on semaglutide lost about 32% more weight over a year when they were also using hormone therapy, likely through estrogen's own effects on visceral fat and lean mass, and the same team later saw the pattern repeat with tirzepatide (Zepbound, Mounjaro). That points to treating a GLP-1 and hormone therapy as one decision, which is what perimenopause and menopause care at Tia coordinates.

Reduces food and alcohol cravings

The clearest thing semaglutide does beyond the stomach is quiet craving. Most women describe food noise going silent, the constant pull toward snacks and sugar easing off, and that same effect on the brain's reward pathways appears to reach other compulsions. A randomized trial of low-dose semaglutide in adults with alcohol use disorder, 71% of them women, found reduced craving and less alcohol consumed. This is early phase 2 work, not grounds for prescribing, but many women notice the alcohol effect without being told to expect it.

Reduces knee pain and increases mobility

Knee osteoarthritis affects women more than men and rarely gets linked to metabolic care. A randomized trial of semaglutide in adults with obesity and knee osteoarthritis found greater reduction in pain and better function than placebo, from less weight through the joint and likely reduced inflammation.

Ozempic side effects in females

Digestive side effects

The most common side effects of Ozempic involve the digestive system. They include nausea, vomiting, diarrhea, abdominal pain, and constipation. Some people also experience reflux, indigestion, burping, bloating, or prolonged feelings of fullness.

Symptoms are often most noticeable when treatment begins or after the dose is increased. For that reason, clinicians generally start semaglutide at a low dose and increase it gradually.

If side effects are difficult, tell your clinician rather than assuming you need to push through them. Depending on your situation, your clinician may recommend staying at the current dose longer, adjusting your eating habits, or reconsidering the treatment plan. Smaller meals, eating slowly, stopping when you feel full, staying hydrated, and limiting foods that reliably worsen

symptoms may help.

Contact a clinician promptly if you have persistent vomiting, trouble keeping fluids down, signs of dehydration, severe or ongoing abdominal pain, and significant abdominal swelling or constipation. Tia can also help with stomach pain issues that stem from another cause and may not be attributed to the medication by default.

Hair loss

Some women notice increased hair shedding during treatment. A systematic review of GLP-1 medications has examined this association. Rapid or substantial weight loss itself can trigger a temporary form of hair shedding called telogen effluvium. Similar shedding can occur after pregnancy, major illness, surgery, or other significant physical stress.

In many cases, hair growth recovers as weight and nutrition stabilize.

But weight loss is not the only possible cause. A cohort study comparing semaglutide and tirzepatide users with people taking metformin also reported increased risk across several types of hair loss. Iron deficiency, thyroid disorders, inadequate protein or calorie intake, hormonal changes, and other conditions can contribute.

If hair loss becomes significant, a Tia clinician can help determine whether nutrition, iron stores, thyroid function, hormonal factors, the medication, or another cause may be involved.

Muscle and bone health

Not all weight lost during treatment is body fat. Body-composition analyses suggest close to 40% of weight lost in some semaglutide data can come from lean mass, although estimates vary by study and method. That matters particularly for women in midlife and beyond, when age- and menopause-related losses in muscle and bone are already important health concerns. A small pilot analysis found no measurable bone-density change over 20 weeks, but longer-term evidence remains limited.

The goal of treatment should therefore be better metabolic health, not simply the fastest possible decline on the scale.

Adequate nutrition and regular resistance exercise can help preserve muscle during weight loss. Protein needs vary based on body size, kidney function, activity level, age, and other medical factors, so individualized nutrition guidance may be appropriate.

Fatigue

Fatigue can occur while taking a GLP-1 medication, but the medication may not always be the only explanation. Strong appetite suppression can make it easy to eat too little. Low calorie intake, inadequate protein, dehydration, iron deficiency, poor sleep, thyroid problems, stress, and perimenopause can all contribute. The relationship between stress and weight can also complicate the picture. Persistent or significant fatigue deserves evaluation rather than simply being accepted as the price of weight loss.

Sex drive and mood

Some women report changes in sexual desire while taking GLP-1 medications, but research in this area is still limited. A narrative review found that human evidence remains limited and mixed. There are plausible explanations in both directions. Nausea, fatigue, inadequate nutrition, or changes in reward pathways could reduce desire. Improved blood sugar, energy, mobility, confidence, or overall health could increase it.

Mood has been studied more extensively. After regulatory reviews of reports of suicidal thoughts in GLP-1 users, the FDA found no evidence of increased risk of suicidal behavior associated with GLP-1 medications. In January 2026 asked manufacturers to remove the warning from the weight-management GLP-1 products that carried it. A systematic review reached a similar overall conclusion, although individual mood changes should still be discussed with a healthcare professional.

Ozempic face

“Ozempic face” is a media nickname rather than a labeled side effect, and the drug does nothing to the skin directly. With weight loss fat leaves the body systemically, so the small fat pads that give cheeks, temples, and the under-eye area their fullness shrink along with everything else, and skin does not always contract to match.

A dermatology review of the phenomenon places it squarely in that category: rapid fat loss amplified by an unusually effective medication. Cleveland Clinic notes it is not limited to Ozempic and follows bariatric surgery or any aggressive weight loss the same way.

Age and pace decide how much “ozempic face” shows. Women already lose facial fat and collagen through midlife, so rapid loss layered on top can read as several years of aging arriving at once, and the distress that causes is real rather than vain. The most effective response is also the least glamorous: a slower rate of weight loss, eating enough protein, resistance training, and sun protection.

Rare but serious risks

Ozempic also carry uncommon but potentially serious risks.

• Thyroid tumors: Semaglutide has a boxed warning related to thyroid C-cell tumors seen in animal studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Pancreatitis: Severe, persistent abdominal pain, sometimes radiating to the back, requires prompt medical evaluation.
• Gallbladder problems: Upper abdominal pain, fever, jaundice, or pale stools may signal gallstones or inflammation.
• Dehydration and kidney problems: Persistent vomiting or diarrhea can cause dehydration and contribute to kidney injury.
• Diabetic eye disease complications: People with diabetic retinopathy should discuss appropriate monitoring with their clinician.

Because GLP-1 medications delay stomach emptying, make sure your surgical and anesthesia teams know you take one before a planned procedure. Follow their specific instructions about eating, drinking, and medication use before surgery.

Ozempic and female fertility, pregnancy, and breastfeeding

Cycles and birth control

Periods often shift on Ozempic, and the change is usually a knock-on effect of losing weight rather than the drug acting on the reproductive system itself. Body fat helps set hormone levels, so when weight drops, cycles can move either way: some women get more regular, others see periods come early, late, or lighter for a while. Ozempic has no ingredient that targets the ovaries or the hormones behind a period, which is why any change tends to track the weight loss rather than the medication directly.

What warrants a visit with a clinician, whatever the cause, is unusually heavy bleeding, months with no period at all, or bleeding between cycles.

When it comes to interaction with birth control pills, Ozempic does not make the pill less effective. Semaglutide's interaction studies found no meaningful change in the hormones that oral contraceptives rely on, so there is no reason to add a backup method. The one real exception is mechanical, not hormonal: in case of vomiting or severe diarrhea within a few hours of a pill can count as a missed dose.

Restored fertility and pregnancy timing

Restored fertility is the effect that catches women off guard. Losing 5% to 10% of body weight can bring back regular ovulation in women whose cycles had stopped, which is why unplanned pregnancies happen on these medications. Anyone not actively trying to conceive should settle contraception before the first injection rather than after.

For planned pregnancy the guidance is firm. The label directs stopping Ozempic at least two months before trying to conceive, because semaglutide stays in circulation for roughly five weeks after the last dose. Tia does not provide obstetric care, but Tia clinicians map that washout against contraception and cycle tracking so the timing is planned rather than discovered.

Breastfeeding

The label states there are no human data, and most guidance defaults to avoiding semaglutide while nursing. The one direct measurement available is more encouraging than that sounds: a 2024 study analyzing milk from eight women taking semaglutide could not detect the drug in any sample, and calculated a worst-case infant dose of 1.26%, well under the 10% threshold generally treated as reassuring.

Molecular size explains why. Semaglutide is a large peptide that struggles to cross into milk, and whatever traces might get through would be largely broken down in an infant's digestive tract. What is missing is long-term infant outcome data, and postpartum GLP-1 use is rising faster than the evidence base, so there’s no definite yes or no answer here.

The takeaway

Semaglutide is a powerful and well-studied medication, but the conversation about Ozempic for women should go beyond weight loss.

Research suggests women may, on average, lose somewhat more weight on GLP-1 medications than men. But every woman’s response is different, and greater weight loss is not automatically better if it comes at the expense of nutrition, muscle, energy, or quality of life.

For women, treatment can also intersect with PMOS (formerly PCOS), menstrual cycles, fertility, pregnancy planning, menopause, muscle and bone health, and cardiovascular and metabolic risk.

The name on the prescription matters. Ozempic and Wegovy both contain semaglutide, but they are not interchangeable in terms of FDA-approved indications and dosing. Evidence from a study of one product or dose should not automatically be assumed to apply to another.

At Tia, metabolic health and weight management are approached as part of the broader picture of women’s health. A metabolic health assessment can look at blood sugar and insulin resistance, hormonal and life-stage changes, nutrition, medications, and other conditions that may be contributing to weight or metabolic concerns. When a GLP-1 medication is clinically appropriate, treatment should include ongoing monitoring and follow-up - not simply a prescription.

Tia’s Metabolic Health & Weight Loss Program provides women’s-focused metabolic evaluation and medically supervised treatment, including access to GLP-1 medications when clinically indicated.

References

1. Novo Nordisk. Ozempic (semaglutide) injection: highlights of prescribing information, revised January 2025. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf

2. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880690/

3. Semaglutide in obesity: unmet needs in men. Diabetes Therapy. https://pmc.ncbi.nlm.nih.gov/articles/PMC9981825/

4. Wang Y, et al. Effects of GLP-1 receptor agonists on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders, 2023. https://pubmed.ncbi.nlm.nih.gov/37940910/

5. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. European Journal of Endocrinology, 2026. https://academic.oup.com/ejendo/article/194/3/S25/8488941

6. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. New England Journal of Medicine, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2413258

7. Alruwaili H, et al. Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the NIH All of Us cohort. Pharmaceuticals, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10891568/

8. Shu Y, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system. Frontiers in Public Health, 2022. https://pubmed.ncbi.nlm.nih.gov/36339230/

9. Castellana E, Chiappetta MR. Semaglutide: a gendered phenomenon, women’s increased vulnerability to adverse drug reactions in the global weight loss trend. Therapeutic Advances in Drug Safety, 2025. https://doi.org/10.1177/20420986251332737

10. Gupta AK, et al. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Science Progress, 2026. https://journals.sagepub.com/doi/10.1177/00368504261444578

11. Herrera HO, et al. Risk of new-onset hair loss with semaglutide and tirzepatide: a TriNetX cohort study. Journal of the American Academy of Dermatology, 2026. https://www.sciencedirect.com/science/article/pii/S0190962226002483

12. New drugs for weight loss: why change in body composition matters and why nutrition and exercise remain paramount. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12668427/

13. Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight or obesity and prediabetes or type 2 diabetes: a 20-week pilot trial post hoc analysis. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12695752/

14. GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research. PubMed. https://pubmed.ncbi.nlm.nih.gov/41870138/

15. U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist medications, January 13, 2026. https://www.fda.gov/media/190557/download?attachment

16. Association of GLP-1 receptor agonists with risk of suicidal ideation and behaviour: a systematic review and meta-analysis. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11823376/

17. Diab H, Fuquay T, Datta P, et al. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11397063/

18. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/